fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Ivermectin systematic review confirms efficacy in covid-19

Written by | 23 Jun 2021

Article written by Christine Clark. The long-awaited systematic review of ivermectin trials from Dr Tess Lawrie’s team at the Evidence-based Medicine Consultancy has now been published in the… read more.

Liposomal drug delivery for ivermectin and vaccines

Written by | 18 Jun 2021

Interview and article by Christine Clark. Liposomal drug delivery holds out the prospect of oral drug administration without the need for water and more economical use of oral… read more.

Solubilised ivermectin improves drug delivery

Written by | 17 Jun 2021

Interview and article by Christine Clark. Patented solubilisation technology improves the bioavailability of oral ivermectin and makes possible the formulation of an ivermectin injection for human use, according… read more.

Metabolic hormone ‘leptin’ linked to poor vaccine response

Written by | 15 Jun 2021

Reduced levels of a metabolic hormone known as leptin is linked to poor vaccine antibody responses in the general population, a University of Queensland study has found. The… read more.

Testing and using drug treatment during a pandemic

Written by | 10 Jun 2021

Interview and article by Christine Clark. Steve Kirsch, CEO of the Covid-19 Early Treatment Fund (CETF) explains how a study in Nepal will advance our understanding of effective… read more.

Treatment of covid-19 with ivermectin + fluvoxamine combination

Written by | 9 Jun 2021

Interview and article by Christine Clark. A combination of fluvoxamine and ivermectin for early treatment of covid-19 is highly effective and should be implemented widely, according to Steve… read more.

Fluvoxamine for early treatment of covid-19

Written by | 8 Jun 2021

Article by Christine Clark. Evidence from trials and real world experience shows that selective serotonin reuptake inhibitors (SSRIs) are effective in treating acute covid and preventing long-haul covid.

Trials of fluvoxamine for covid-19

Written by | 8 Jun 2021

Interview and article by Christine Clark. Early treatment of covid-19 with fluvoxamine has been remarkably effective in two trials, one of which was funded by the Covid-19 Early… read more.

Mild COVID-19 induces lasting antibody protection, study finds

Written by | 4 Jun 2021

People who have had mild illness develop antibody-producing cells that can last lifetime Washington University School of Medicine Months after recovering from mild cases of COVID-19, people still… read more.

MHRA approves Ad26.COV2-S [recombinant] for active immunisation against COVID-19 within the United Kingdom – Janssen

Written by | 30 May 2021

Ad26.COV2-S [recombinant] a single-dose coronavirus vaccine from Janssen, part of Johnson & Johnson, has been approved by the MHRA (UK) and is indicated for active immunisation to prevent… read more.

Four-month TB therapy proves as effective as 6-month standard regimen

Written by | 24 May 2021

Four months of multi-drug therapy that included rifapentine and moxifloxacin treated active tuberculosis (TB) as effectively as the standard six-month regimen in a multinational study, cutting treatment time… read more.

Prophylaxis with ivermectin and the next steps

Written by | 22 May 2021

Interview and article by Christine Clark. Ivermectin should be used for prophylaxis and treatment of covid-19 throughout India, according to Dr Suryakant (Head of the Department of Respiratory… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.